培美曲塞联合奈达铂治疗老年晚期非小细胞肺癌患者的近、远期疗效及对不良反应的影响  

Short-term, long-term efficacy of pemetrexed combined with nedaplatin in elderly patients with advanced non-small cell lung cancer and the influence on adverse reactions

作　　者：张小燕 兰飞[1] 张义灵[1] ZHANG Xiao-yan;LAN Fei;ZHANG Yi-ling(Tangdu Hospital,Xi'an 710038,China)

机构地区：[1]唐都医院

出　　处：《临床医学研究与实践》2020年第2期26-27,共2页Clinical Research and Practice

摘　　要：目的研究培美曲塞联合奈达铂治疗老年晚期非小细胞肺癌患者的近、远期疗效及对不良反应的影响。方法将我院收治的108例老年非小细胞肺癌患者采用随机数字法分为对照组和观察组,各54例。对照组给予培美曲塞治疗,观察组给予培美曲塞联合奈达铂治疗。比较两组患者的近、远期疗效以及不良反应发生情况。结果治疗后,两组的近期疗效无显著差异(P>0.05),但观察组的CR率高于对照组(P<0.05)。两组的远期疗效和不良反应发生率均无显著差异(P>0.05)。结论培美曲塞联合奈达铂对老年晚期非小细胞肺癌患者的近期疗效优于单一使用培美曲塞,易被患者耐受,但两种方法的远期疗效和不良反应发生情况无显著差异。Objective To study the short-term, long-term efficacy of pemetrexed combined with nedaplatin in elderly patients with advanced non-small cell lung cancer and the influence on adverse reactions. Methods A total of 108 elderly patients with non-small cell lung cancer admitted in our hospital were divided into control group and observation group by random number method, with 54 cases in each group. The control group was treated with pemetrexed, and the observation group was treated with pemetrexed combined with nedaplatin. The short-term, long-term efficacy and adverse reactions were compared between the two groups. Results After treatment, there was no significant difference in short-term efficacy between the two groups(P>0.05), but CR rate of the observation group was higher than that of the control group(P<0.05).There were no significant differences in long-term efficacy and incidences of adverse reactions between the two groups(P >0.05). Conclusion The pemetrexed combined with nedaplatin in elderly patients with advanced non-small cell lung cancer has better short-term efficacy than the pemetrexed alone, it is easy to lerated by patients, but there are no significant differences in the long-term efficacy and adverse reactions between the two methods.

关 键 词：培美曲塞 奈达铂 晚期非小细胞癌 近期疗效 远期疗效 

分 类 号：R734.2[医药卫生—肿瘤]